Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof
US9994923B2 · kind B2 · utility
2Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2009 |
| Grant date | Jun 12, 2018 |
| Priority date | — |
| Expiry date | Aug 28, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Neutralizing PCSK9 variants that interact with low density lipoprotein receptor (LDLR) are described. Methods and compositions for treating disorders by administering a pharmaceutically effective amount of a neutralizing PCSK9 variant are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.